M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD
German healthcare company Fresenius AG plans to step up restructuring at its nutrition and infusion therapy subsidiary, Fresenius Kabi.
The restructuring, which will cost an additional EUR25m in one-off charges this year, is expected to significantly improve profitability at Kabi next year.
The additional restructuring will focus on production at Fresenius Kabi's parenteral nutrition business, which supplies intravenous infusion products. Research and development activities …